LIXTE

Transforming cancer treatment with Protein Phosphatase 2A inhibitors. Unveiling the first of a novel class of therapeutic agents. $LIXT

[LIXTE @LixteBiotech]

LIXTE Biotech Holdings Inc. (NASDAQ: $LIXT) and Liora Technologies are advancing a multi-modal cancer platform, combining the LiGHT proton therapy system with LB-100 to potentially improve treatment precision and outcomes for patients.

Read more: https://t.co/SZnyyr7Q3A

[LIXTE @LixteBiotech]

LIXTE Biotech Holdings Inc. ( $LIXT ) has appointed Sidney Braun as CEO of Liora Technologies, bringing 20+ years of global healthcare and strategic advisory experience to advance the LiGHT proton therapy platform.

Read more: https://t.co/7XN2JlDQui
#BioTech #Healthcare

[LIXTE @LixteBiotech]

LIXTE Biotech Holdings Inc. has acquired Liora Technologies, adding the LiGHT proton therapy platform to advance precision cancer care and expand our integrated oncology innovation strategy.

Read more: https://t.co/PJAxPCIlDR
#Biotech #CancerResearch $LIXT

[LIXTE @LixteBiotech]

We’ve acquired Liora Technologies, bringing the proprietary LiGHT proton therapy system into the LIXTE family. Paired with LB-100, we’re advancing precision radiotherapy + combination cancer care to set a new standard in treatment.

Read more: https://t.co/UR3t2C3F1J
#therapy

[LIXTE @LixteBiotech]

Read more about our #LB100 cancer trials in collaboration with GSK and Roche in @PharmaNowGlobal. $LIXT

https://t.co/6YU0Uw95Wn

[LIXTE @LixteBiotech]

Great news … the @LurieCancer of @NorthwesternU has been added as a second site in a clinical trial combining our LB-100 with GSK’s Dostarlimab to treat ovarian clear cell cancer. $LIXT #LB100

https://t.co/b51ghhF9FR

[LIXTE @LixteBiotech]

Click the video link below to learn more about our ovarian cancer trial with @GSK conducted by @MDAndersonNews. $LIXT #LB100 #dostarlimab

https://t.co/r3ct1QKv1E

[Cancer Grand Challenges @CancerGrand]

René Bernards, Professor of Molecular Carcinogenesis @NKI_nl and member of the #CancerGrandChallenges Scientific Committee, attended our first think tank in Paris.

Read his reflections 👇

[LIXTE @LixteBiotech]

In case you missed it, click below to watch a replay of CEO Bas van der Baan present at the Investor Summit Group Summer 2024 Virtual Conference. $LIXT

https://t.co/IABhTRpUvF

[LIXTE @LixteBiotech]

This morning we announced that we received a patent allowance from the @uspto titled, "Oxabicycloheptanes for Modulation of Immune Response,” for combining our hashtag #LB100 compound with various innovative #cancer immunotherapies. $LIXT #Lixte

https://t.co/VjcvCZD6Of

[LIXTE @LixteBiotech]

NEWS ALERT: This morning we announced the dosing of the first patient of a new clinical trial with @NKI_nl and @Roche for treatment of metastatic colorectal cancer. $LIXT #LB100 #cancertreatment

https://t.co/l6mqvnqKt4

[LIXTE @LixteBiotech]

Watch our CEO Bas van der Baan present at tomorrow's Summer 2024 Virtual Conference at 2 p.m. EDT. Click below to register. $LIXT

https://t.co/R5ALNADYJV

[LIXTE @LixteBiotech]

$LIXT will be presenting at two upcoming investor conferences:

The Investor Summit Summer 2024 Virtual Conference on Tuesday, August 20.

The H.C. Wainwright 26th Annual Global Investor Conference September 9-11 .

Register here:

https://t.co/D2lMdijRju

#Lixte #LB100

[LIXTE @LixteBiotech]

In this @Clin_Info_News story, Matheus Henrique Dias of the @NKI_nl explains "paradoxical intervention” and how the double stimulation by #LB100 and WEE1 inhibition leads to mitotic disaster and cancer cell death. #Lixte $LIXT #CancerTreatment

https://t.co/NdEayyDYyj

[LIXTE @LixteBiotech]

It’s summer ☀️⛱️🕶️🩴but we’ve been busy the past couple of months, from announcing a new chief medical officer to starting a new clinical trial with Roche and the Netherlands Cancer Institute. Click to read recent highlights below. $LIXT #Lixte

https://t.co/3ygS34Vbm0

[LIXTE @LixteBiotech]

Data from researchers at @UCSFMedicine, @cityofhope
and the @NKI_nl recently published in @MolOncology demonstrates that PP2A inhibition could enhance the responsiveness of tumors to ICB and other T cell-mediated therapies. #LB100 $LIXT #CancerTreatment

https://t.co/FD1FJEkowP

[LIXTE @LixteBiotech]

NEW CLINICAL TRIAL: This morning we announced a new clinical trial with @Roche and @NKI_nl to test recent findings that show our #LB100 enhances #immunotherapy in the treatment of colon cancer.

$LIXT #Lixte #CancerTreatment

https://t.co/n2ubbLpJv7

[LIXTE @LixteBiotech]

New pre-clinical data from researchers at the @NKI_nl published in @EMBO show that our #LB100 lead molecule can turn immunologically “cold” tumors “hot,” potentially enhancing the benefit #immunotherapy. $LIXT

https://t.co/HYM5PDey3M

[LIXTE @LixteBiotech]

This morning we appointed Dr. Jan Schellens as our new chief medical officer. Click the link below to read more on today's appointment. $LIXT #Lixte #oncology #LB100

https://t.co/ORmoIESW2m

[LIXTE @LixteBiotech]

Click below to watch CEO Bas van der Baan discuss new pre-clinical data that shows how the deliberate hyperactivation of oncogenic signaling combined with our #LB100 can force #cancer cells to give up their cancer-causing properties. ⬇ ⬇ ⬇ ⬇ ⬇ $LIXT

https://t.co/KLJfUwu5QI